2311: Galliford Try returns to profit & resumes dividend, Piri increases digital asset investment & Vadim Alexandre on Allergy Therapeutics

Galliford Try returns to profitability and resumes the dividend. Pires Investment talks about their increase in exposure to digital assets. Vadim Alexandre discusses Allergy Therapeutics.